Literature DB >> 22328049

[Anemia caused by cancer in the context of palliative care].

Marion Altinger1, Florian Strasser.   

Abstract

Tumor anemia is very common in patients with cancer. The causes are very diverse and the parameter value depends on several factors. If this however develops to be symptomatic it may adversely impact health related quality of life. Erythropoietin or blood transfusion provides options for treatment. However, these are not always uneventful. There could also be a lack of response to Erythropoietin. This case report describes the complexity of tumor anemia. It also includes a more detailed discussion on the Fatigue Syndrome, which is one of the most common symptoms of patients with cancer. In the context of palliative care there is often the question of alternatives for improving the quality of patients life. Some kinds of treatment may also cause the opposite effect. A multidimensional assessment should help to approach this difficult issue and to find ways for a meaningful treatment of the symptoms of anemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22328049     DOI: 10.1007/s10354-011-0047-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  15 in total

1.  Survey of blood transfusion practice for palliative care patients in Yorkshire: implications for clinical care.

Authors:  Elizabeth Brown; Mike Bennett
Journal:  J Palliat Med       Date:  2007-08       Impact factor: 2.947

2.  Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients.

Authors:  Elisabet Lindholm; Peter Daneryd; Ulla Körner; Anders Hyltander; Marita Fouladiun; Kent Lundholm
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

Review 3.  Anemia in cancer.

Authors:  M Dicato; L Plawny; M Diederich
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

4.  Supportive treatment for anemic cancer patients.

Authors:  Gudrun M I Pohl; Heinz Ludwig
Journal:  Wien Med Wochenschr       Date:  2004-05

5.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 6.  Fatigue in palliative care patients -- an EAPC approach.

Authors:  Lukas Radbruch; Florian Strasser; Frank Elsner; Jose Ferraz Gonçalves; Jon Løge; Stein Kaasa; Friedemann Nauck; Patrick Stone
Journal:  Palliat Med       Date:  2008-01       Impact factor: 4.762

7.  Blood transfusion and its benefits in palliative care.

Authors:  C Gleeson; D Spencer
Journal:  Palliat Med       Date:  1995-10       Impact factor: 4.762

8.  The use of blood transfusions and erythropoietin-stimulating agents in Swedish palliative care.

Authors:  Ulla Martinsson; Staffan Lundström
Journal:  Support Care Cancer       Date:  2008-09-05       Impact factor: 3.603

9.  The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.

Authors:  Ralph Boccia; Tom Lillie; Dianne Tomita; Lodovico Balducci
Journal:  Oncologist       Date:  2007-05

10.  Cancer-related fatigue: clinical practice versus practice guidelines.

Authors:  Doranne L Hilarius; Paul H Kloeg; Elsken van der Wall; Manon Komen; Chad M Gundy; Neil K Aaronson
Journal:  Support Care Cancer       Date:  2010-03-19       Impact factor: 3.603

View more
  1 in total

1.  20(S)-Protopanaxdiol Suppresses the Abnormal Granule-Monocyte Differentiation of Hematopoietic Stem Cells in 4T1 Breast Cancer-Bearing Mouse.

Authors:  Wen-Qin Guo; Ying-Ge Chen; Rong-Zhen Shi; Kai He; Jian-Feng Wang; Jin-Hui Shao; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.